Drug Profile
Research programme: epigenetic inhibitors - EPIGeNE Therapeutics
Latest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator NEOMED Therapeutics 1
- Developer EPIGeNE Therapeutics
- Class Antineoplastics
- Mechanism of Action Bromodomain and extraterminal domain protein inhibitors; P300-CBP transcription factor inhibitors; Transcription factor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for research development in Cancer in USA
- 28 Feb 2018 Early research in Cancer in USA (unspecified route)